SynthesisFrontiers in oncology2021

Balancing the Risk-Benefit Ratio of Immune Checkpoint Inhibitor and Anti-VEGF Combination Therapy in Renal Cell Carcinoma: A Systematic Review and Meta-Analysis.

Li Tao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.